Evidence map›Paper›PMID 39611736›Full record

ReviewChemical communications (Cambridge, England)2024

Plugging synthetic DNA nanoparticles into the central dogma of life.

Kayla Neyra, Sara Desai, Divita Mathur

Abstract readReview
In one paragraph

Review in Chemical communications (Cambridge, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kayla NeyraDepartment of Chemistry, Case Western Reserve University, Cleveland, OH 44106, USA. dxm700@case.edu.ORCID 0009-0001-6988-7119
Sara DesaiDepartment of Biochemistry, Case Western Reserve University, Cleveland, OH 44106, USA.ORCID 0009-0005-6025-4509
Divita MathurDepartment of Chemistry, Case Western Reserve University, Cleveland, OH 44106, USA. dxm700@case.edu.ORCID 0000-0002-3537-7292

Funding

Cytosolic Access and Instability of DNA nanoparticlesR00EB030013 · NIBIB · CASE WESTERN RESERVE UNIVERSITY · PI MATHUR, DIVITA · 2022 to 2024
$747k
NIBIB NIH HHS R00 EB030013
6 · The paper itself

Abstract

Synthetic DNA nanotechnology has emerged as a powerful tool for creating precise nanoscale structures with diverse applications in biotechnology and materials science. Recently, it has evolved to include gene-encoded DNA nanoparticles, which have potentially unique advantages compared to alternative gene delivery platforms. In exciting new developments, we and others have shown how the long single strand within DNA origami nanoparticles, the scaffold strand, can be customized to encode protein-expressing genes and engineer nanoparticles that interface with the transcription-translation machinery for protein production. Remarkably, therefore, DNA nanoparticles - despite their complex three-dimensional shapes - can function as canonical genes. Characteristics such as potentially unlimited gene packing size and low immunogenicity make DNA-based platforms promising for a variety of gene therapy applications. In this review, we first outline various techniques for the isolation of the gene-encoded scaffold strand, a crucial precursor for building protein-expressing DNA nanoparticles. Next, we highlight how features such as sequence design, staple strand optimization, and overall architecture of gene-encoded DNA nanoparticles play a key role in the enhancement of protein expression. Finally, we discuss potential applications of these DNA origami structures to provide a comprehensive overview of the current state of gene-encoded DNA nanoparticles and motivate future directions.

Indexed as

DNANanoparticlesHumansNanotechnologyDNA

Identifiers

PMID39611736
PMCPMC11606385

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.